Mysoline (Primidone)

Primidone is converted in the liver to phenobarbital, a compound that enhances GABA‑mediated inhibition of neuronal firing. This increased inhibition stabilises neuronal membranes, decreasing the abnormal electrical activity that causes seizures and tremor.

The appropriate dose of Mysoline is determined by the prescribing clinician based on the patient’s age, weight, seizure type, and response to therapy. Dosage adjustments may be required for renal or hepatic impairment, and the prescriber will provide specific instructions.

Safety data for primidone in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Mysoline, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Primidone is similar to phenobarbital in its mechanism but is often preferred for its additional efficacy in essential tremor. Compared with newer agents, it may have a broader side‑effect profile and requires careful monitoring, but it remains a cost‑effective option for many seizure types.

Mysoline tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Mysoline is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water. The exact schedule—once daily, twice daily, or more—depends on the individual treatment plan.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, blood disorders like agranulocytosis, hepatic injury, and the emergence of suicidal thoughts or severe depression. Patients should seek immediate medical attention if they notice any of these symptoms.

Mysoline is contraindicated in patients with known hypersensitivity to primidone or phenobarbital, those with severe hepatic impairment, and individuals who are currently taking other barbiturates that could cause additive toxicity. Clinicians should evaluate each patient’s medical history before prescribing.